Please ensure Javascript is enabled for purposes of website accessibility

A Shot in the Arm for Novartis' Pipeline

By Brian Orelli, PhD - Updated Apr 5, 2017 at 7:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company picks up the rights to a vaccine that fights a virus.

Vaccines may not be as sexy as cures for major diseases, but they're still big business for big pharma.

On Monday, Novartis (NYSE:NVS) added to its collection a license for privately held AlphaVax's cytomegalovirus (CMV) vaccine for $20 million, plus potential milestone payments. CMV, a member of the herpes virus family, affects people with weakened immune systems, like infants and people with AIDS, and can lead to several things, such as gastrointestinal disease in adults or mental retardation in newborns.

Novartis will take over the development of the vaccine next year when it enters phase 2 trials. At the end of that, Novartis will have an option to buy 4 million shares in AlphaVax. Not a big surprise that the company threw in the option, given its propensity to own parts of companies -- Roche and Alcon (NYSE:ACL), for example.

The $20 million up front seems like a cheap bet for Novartis, given that the potential for vaccines is pretty large. Wyeth's (NYSE:WYE) pneumonia vaccine, Prevnar, had $2.1 billion in sales during the first nine months of the year, and GlaxoSmithKline's (NYSE:GSK) combination vaccines Infanrix and Pediarix registered $952 million in sales over that time.

While the risk of failure for vaccines during clinical trials is probably lower than that of drugs that treat diseases, vaccines aren't immune to failure. Last week, for instance, Merck (NYSE:MRK) dropped its support for Dynavax Technologies' hepatitis C vaccine after the Food and Drug Administration put a clinical hold on the trials because of the occurrence of a rare blood vessel disease earlier this year.

Vaccines are unsung heroes of pharmaceutical companies. They contribute nicely to the revenue stream: Novartis' vaccines and diagnostic business posted a 20% year-over-year increase in revenue to $1.27 billion during the first nine months of the year, for instance. But, because they prevent diseases rather than cure them, vaccines aren't as sexy and don't garner as much attention as they probably should. It might be time for Foolish investors to take a second look.

Glaxo is an Income Investor recommendation. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novartis AG Stock Quote
Novartis AG
NVS
$85.22 (-0.70%) $0.60
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$91.04 (0.50%) $0.45
GSK Stock Quote
GSK
GSK
$34.70 (-1.59%) $0.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.